Genprex, Inc. (NASDAQ:GNPX) Sees Significant Drop in Short Interest

Genprex, Inc. (NASDAQ:GNPX) saw a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 342,100 shares, a decline of 5.9% from the October 31st total of 363,400 shares. Based on an average daily trading volume, of 9,330,000 shares, the short-interest ratio is presently 0.0 days. Currently, 4.3% of the shares of the company are sold short.

Genprex Trading Up 0.9 %

GNPX stock traded up $0.01 during trading on Tuesday, reaching $1.10. 1,795,534 shares of the company’s stock were exchanged, compared to its average volume of 1,901,165. Genprex has a 1-year low of $0.28 and a 1-year high of $14.40. The company’s fifty day moving average price is $1.19 and its 200-day moving average price is $1.44.

Hedge Funds Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Armistice Capital LLC increased its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 218,000 shares of the company’s stock after acquiring an additional 120,132 shares during the period. Armistice Capital LLC owned approximately 10.39% of Genprex worth $411,000 at the end of the most recent quarter. Institutional investors own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.